Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.
Subsequent systemic treatments after first-line FIrB/FOx
| Overall (85 patients) | |
|---|---|
|
| |
| Maintenance therapy (5-fluorouracil/ | 8 (9.4) |
| capecitabine–bevacizumab), n (%) | |
| Progression events, n | 72 (84.7) |
| Second-line chemotherapy, n (%) | 51 (70.8) |
| FIrB/FOx rechallenge | 14 (27.4) |
| AntiEGFR-based regimens | 13 (25.5) |
| Other bevacizumab-based regimens | 9 (17.6) |
| Aflibercept-based regimens | 6 (11.8) |
| Third-line systemic therapy, n (%) | 27 (37.5) |
| Fourth-line systemic therapy, n (%) | 13 (18.1) |
